Virtual Incision Corporation, a medical device company pioneering a first-of-its-kind miniaturized surgical robot, announced it has raised $20 million in a Series B+ financing led by returning investor Bluestem Capital, with participation from returning investor PrairieGold Venture Partners.
The companies we back all have one thing in common: they want to change the world. Some of the teams we’ve partnered with are
- detecting cancer very early on using simple blood tests
- growing plants that create inexpensive sugar
- making solar electricity on the roof that is less expensive than the grid
- performing robotic surgery inside the body
- developing biorefineries that make fuels and chemicals that are cheaper than oil
Revolutionary solutions to change the world. If this is what your company is about, we’d like to talk with you.
“Extremely pleased with the company and the rep that helped me out. Everything was explained to me in a way I could understand and the process was smooth and easy!.”
Neil Borton
The Food and Drug Administration granted the company an investigational device exemption, which green lights a clinical study of the platform, called MIRA, to be carried out at a limited number of U.S. hospitals. This is a crucial step toward FDA approval of MIRA, which stands for “miniaturized in vivo robotic assistant.”.